San Antonio-based medical device start-up Hera Biotech has closed an oversubscribed $1.9 million seed financing round to support the company’s commercialization strategy for its category-defining non-surgical diagnostic test for endometriosis, MetriDxTM. The funds will be used to complete an in-patient human clinical study, expand Hera’s IP portfolio, and support a regulatory pathway with the US FDA.

Hera Biotech, Inc. was formed to apply advances in biotechnology to address unmet needs in the field of women’s health and reproductive medicine. Hera’s initial goal is to commercialize MetriDx™, a novel, non-surgical method for the definitive, early diagnosis and staging of endometriosis.

https://www.herabiotech.com/

Hera Biotech Closes Oversubscribed $1.9 Million Seed Raise For Novel Diagnostic Test For Endometriosis

Description

Company Information

Related People

Hera Biotech Closes Oversubscribed $1.9 Million Seed Raise For Novel Diagnostic Test For Endometriosis

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Company Information